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Abstract During the past years, non-neuronal vascular nico-
tinic acetylcholine receptors (nAChRs) increasingly have
gained interest in cardiovascular research, as they are known
to mediate the deleterious effects of nicotine and nitrosamines,
components of tobacco smoke, on the vasculature. Because
smoking is a major risk factor for the development of athero-
sclerosis, it is obvious that understanding the pathophysiolog-
ic role of nAChRs in the atherosclerotic disease process, as
well as in the development of new diagnostic and therapeutic
nAChR-related options, has become more important. Accord-
ingly, we briefly summarize the pathophysiologic role of vas-
cular nAChRs in the atherosclerotic disease process. We also
provide an overview of currently available nAChR positron
emission tomography (PET) tracers and their performance in
the noninvasive imaging of vascular nAChRs, as well as po-
tential nAChR PET tracers that might be an option for vascu-
lar nAChR PET imaging in the future.
Keywords Nicotinic acetylcholine receptors . Positron
emission tomography . Atherosclerosis
Introduction
Interest in non-neuronal vascular nicotinic acetylcholine
receptors (nAChRs) has been increasing in cardiovascu-
lar research because they are known to mediate the del-
eterious effects of nicotine and nitrosamines, compo-
nents of tobacco smoke, on the vasculature. Smoking
is a major, if not the greatest, risk factor for the devel-
opment of atherosclerosis. Therefore, understanding the
pathophysiologic role of nAChRs in the atherosclerotic
disease process, and consequently, the development of
new diagnostic and therapeutic nAChR-related options,
has become more important. The first steps in that di-
rection—development of new noninvasive imaging strat-
egies for nAChRs by means of positron emission to-
mography (PET)—have been taken and, along with the
pathophysiologic role of nAChRs in atherosclerosis, are
described in this review article.
Atherosclerosis
The clinical consequences of atherosclerosis—myocardial in-
farction and stroke—remain themost common causes of death
in Europe and worldwide [1–3]. It is well known that athero-
sclerotic progression and severity are linked to many clinical
risk factors, including hyperlipidemia, diet, diabetes, obesity,
hypertension, and nicotine abuse.
Atherosclerosis reflects a pathologic process in the
arterial wall, where endothelial injury results in accumu-
lation of lipids and inflammatory cells in the intima [1,
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4••]. The blood-derived monocytes differentiate into
macrophages, which express scavenger receptors,
allowing them to ingest oxidized lipids and become
foam cells [1, 5]. Early atherosclerotic plaques originate
as fatty streaks, which are lipid-filled macrophage foam
cells consisting of fat, cholesterol, and other biologic
components [4••]. As these lesions further expand, foam
cell apoptosis and necrosis result in continuing accumu-
lation of lipids and necrotic debris. This process leads
to the development of a highly thrombogenic lipid core
and an expansion of the plaque within the arterial wall.
In addition, via various signaling cascades, soluble fac-
tors are released, mediating platelet adhesion as well as
proliferation and migration of vascular smooth muscle
cells (VSMCs) from the tunica media to the intima.
The VSMCs compose a stabilizing, collagen-rich, fi-
brous cap, which covers the lipid core, resulting in
highly vascularized stable or unstable vulnerable plaques
[1, 6].
Nicotinic Cholinergic Pathway
During recent years, cardiovascular researchers became
increasingly interested in nAChRs, the most frequent
cholinergic receptors in the central nervous system
(CNS), as non-neuronal nAChRs are known to mediate
the deleterious effects of nicotine and nitrosamines,
components of tobacco smoke, on the vasculature. Be-
cause smoking is a major risk factor for the develop-
ment of atherosclerosis and consequently, stroke and
myocardial infarction, it has become clear that under-
standing the pathophysiologic role of nAChRs in the
atherosclerotic disease process, as well as the develop-
ment of new diagnostic and therapeutic nAChR-related
options, is more important than ever. In this review, we
focus mainly on the potential of noninvasive imaging of
nAChRs by means of PET combined with CT (PET/CT)
or MRI (PET/MRI) not on the physiologic or patho-
physiologic role of vascular nAChRs in cardiovascular
disease; however, we provide a brief summary on the
physiology and proatherogenic effects of nAChRs in the
vasculature [4••, 7].
nAChRs are a heterogeneous family of ligand-gated
transmembrane ion channel receptors that mediate fast
synaptic transmission [8–11]. They work as a regulator
of excitatory neurotransmission, and nAChR activity in
the CNS has been found to regulate physiologic func-
tions such as sleep, fatigue, arousal, central processing
of pain, and cognitive functions [8, 10]. From a patho-
physiologic point of view, nAChRs were identified as
contributing to the pathogenesis of several diseases, in-
cluding myasthenia gravis, Alzheimer’s disease, and
Parkinson’s disease [8, 10, 12]. This discovery led to
the development of PET-feasible 18F-labeled radiotracers
for noninvasive diagnosis of these neurodegenerative
disorders [13–15].
Non-neuronal Vascular nAChRs
It is now known that nAChRs are expressed ubiquitously in
almost all cells in the blood vessels. There, these vascular
nAChRs accelerate the atherogenic process [4••]. The struc-
ture of non-neuronal nAChRs such as vascular nAChRs close-
ly resembles that found in CNS nAChRs: a pentamer com-
posed of distinct subunits arranged tightly around a central
pore [7]. So far, 12 different nAChR subunits, α2 to α10
and β2 to β4 have been identified that can form heteromeric
nAChRs: for example, α4β2 nAChRs. In contrast, the
homomeric receptors (e.g., α7-nAChRs) are made up of five
α-subunits.
nAChRs have been found on human VSMCs (α2, α3, α4,
α5, α7, α10); human aortic endothelial cells (α3, α5, α7,
α10, β2, β3, β4); human platelets (α7); human mononuclear
leukocytes (α7, β2); human macrophages (α1, α7, α10); B
lymphocytes (α3, α4, α5, α7); and T lymphocytes (α3, α4,
α7, β2, β4) [4••, 7, 10, 16–19].
The endogenous ligand for nAChRs is acetylcholine
(ACh); however, nicotine and tobacco-specific nitrosa-
mines (e. g., NNK [4-(methylnitrosamino)-1-(3-pyri-
dyl)-1-butanone], NNN [N0-nitrosonornicotine], DEN
[N-diethylnitrosamine]) also are high-affinity nAChR li-
gands [4••]. Binding of the ligand to the receptor leads
to a conformational change in the nAChR, resulting in
opening of the ion channel and transmission of the sig-
nals. Charged amino acids line the central pore and
select the ions that pass through the channel [4••].
nAChR-Mediated Atherogenic Effects
The non-neuronal nicotinic cholinergic pathway regulates
several components of atherogenesis, including inflammation,
VSMC phenotype, proliferation, migration, and plaque neo-
vascularization [4••]. The latter process is characterized by a
network of capillaries, which originates from the adventitial
vasa vasorum and extends into the intimal layer of atheroscle-
rotic lesions [4••].
NNK, a tobacco carcinogen and high-affinity ligand
to nAChRs as described earlier, appears to cause endo-
thelial cell apoptosis [4••, 20]. However, these findings
are debated, as other groups found NNK to facilitate
angiogenesis in lung and gastric cancer [21, 22]. Nico-
tine promotes chemotaxis and migration of rat and hu-
man VSMCs, as well as preventing VSMCs from un-
dergoing apoptosis induced by serum deprivation, sug-
gesting that growth and migration of VSMCs are
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enhanced by both these pathways [16, 23–27]. Heeschen
et al. [28] investigated the effect of nicotine on VSMC
migration, proliferation, growth, and neovascularization
of advanced atherosclerotic plaques in mice and found a
significantly larger median plaque area and a higher
percentage of vascularized plaques in nicotine-treated
mice compared with a control group. Their results indi-
cated a nicotine-related stimulation of plaque growth
related to increasing plaque neovascularization rather
than VSMC proliferation [28, 29]. As mentioned earlier,
nicotine stimulates VSMC migration depending on
nAChR activity [16, 24, 25, 30]. Important signaling
pathways that contribute to this nAChR-mediated
VSMC migration are elevation of the early growth re-
sponse gene 1 (Erg-1), increased calcium influx, activa-
tion of EGFR, increased telomerase activity, and phos-
phorylation of Ets-like gene 1 [25, 30, 31]. In addition,
nicotine also was found to upregulate levels of proin-
flammatory cytokines, i.e., IL-6, MCP-1, and NF-κB, in
human aortic VSMCs [32].
Nicotine induces the production of growth factors such
as TGF-α, TGF-β, PDGF-BB, VEGF, and FGF-2 [25, 33,
34]. These growth factors were shown to stimulate VSMC
proliferation (PDGF-BB, TGF-α, and FGF-2) and to pro-
mote the migration of human VSMCs and plaque neovas-
cularization (VEGF) [6, 33, 34]. They also cause
contractile-to-synthetic transition, cytoskeletal remodeling,
enhanced proliferation, and migration of VSMCs—path-
ways that facilitate formation of the intimal lesions char-
acteristic of atherosclerosis (PDGF-BB) [6, 33, 34]. Fur-
thermore, endothelial permeability appears to be enhanced
by increased expression of growth factors. This process
also is known to contribute to plaque neovascularization
and atherosclerotic progression [4••, 35, 36].
As described earlier, nAChRs are found on several
immune cells. The influx of these immune cells, includ-
ing macrophages, into the arterial wall is known to con-
tribute to atherosclerotic plaque formation [37]. It there-
fore is likely that nicotine or other stimulating agents
act on these immune cells and also on endothelial pro-
genitor cells to facilitate neovascularization of plaques
as well as thrombosis [4••]. Nicotine enhances the ad-
hesion of human microvascular endothelial cells to
monocytes, a process stimulated by upregulation of the
cytokines TNF-α and IL-β [4••, 17]. Furthermore,
Aicher et al. [38] showed that nicotine caused a seven-
fold increase in proinflammatory cytokine IL-12 and IL-
10 levels in human dendritic cells compared with un-
treated controls [38]. This upregulation was mediated
via α7-nAChRs on the dendritic cells. The activation
of dendritic cells by nicotine augments their capacity
to stimulate T cell proliferation and, as mentioned ear-
lier, to secrete cytokines. Both these pathways may
contribute significantly to the proatherogenic effects of
nicotine.
PET Imaging of Vascular nAChRs
PET is the most advanced technique for noninvasive
molecular imaging in vivo [39–42]. It allows three-
dimensional quantitative detection of the distribution of
radiolabeled ligands with high resolution and sensitivity.
PET thereby provides functional images of biochemical
and physiologic processes in different organ systems
[40, 43]. This advanced nuclear medicine technique
has been integrated into clinical routine for in vivo im-
aging mainly in oncology but also in cardiology and
neurology and for assessing inflammation [44]. Further-
more, PET is considered a highly sophisticated device
for experimental animal research and has been proven to
facilitate the translational process in the development of
new radiotracers [40, 45, 46]. Clinical PET cameras are
now available with a spatial resolution of about 2 to
3 mm, allowing the investigation of radioligand distri-
bution even within small target tissues in both animals
and humans [40, 47, 48].
Today, almost all clinical PET systems are equipped
with CT within one device, allowing anatomic correla-
tion of the PET findings and therefore the combination
of functional (PET) and morphologic (CT) imaging in
one session. Whereas BPET-only^ systems are now quite
rare, the newest development involves hybrid PET/MRI
scanners. This challenging imaging technique combining
PET and MRI has been used in routine clinical practice
for the past few years and has shown much promise in
further broadening the spectrum of indication for hybrid
functional and morphologic noninvasive imaging.
PET imaging for nAChRs initially was used to eval-
uate cerebral nAChR distribution in patients with neu-
rodegenerative disorders such as Alzheimer’s and
Parkinson’s disease [13–15]. The first attempts focused
on imaging cerebral α4β2-nAChRs, which were shown
to be significantly reduced in both Alzheimer’s and
Parkinson’s disease [15]. Along with further develop-
ment of 18F-labeled PET tracers for clinical imaging of
cerebral α4β2-nAChRs, more recent approaches have
focused on development and evaluation of α7-nAChR
PET tracers, which are now available and awaiting fur-
ther preclinical and clinical evaluation [49, 50••, 51–53,
54••, 55].
In 2006, our group published the first attempts to
image non-neuronal α4β2-nAChRs [56]. It is known
that stimulation of the parasympathetic autonomic sys-
tem decreases heart rate and cardiac contractility and
that this pathway is mediated by acetylcholine acting
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on intracardiac ganglionic nAChRs and cardiac musca-
rinic acetylcholine receptors (mAChRs). Therefore, we
aimed to assess the distribution of cardiac α4β2-
nAChRs with a dedicated α4β2-nAChR PET ligand
([18F]-2-fluoro-A85380) in humans. Furthermore, we
attempted to evaluate whether the cardiac distribution
of α4β2-nAChRs differs between healthy controls and
patients with known Parkinson’s disease or multiple sys-
tem atrophy (MSA), as it already was demonstrated that
cerebral distribution of these nAChRs is reduced in the-
se patient populations.
Five healthy volunteers without cardiac disease and six
patients with either Parkinson’s disease or MSA without
additional overt cardiac disease were evaluated with [18F]-
2-fluoro-A85380 PET imaging to assess cardiac parasym-
pathetic innervation and the putative impact of both dis-
orders thereon. Whole-body PET scans were performed
on a Siemens PET/CT Biograph (Siemens, Erlangen,
Germany) 75.4±6.7 min after intravenous injection of
371±58 MBq of the tracer. The average count rate density
of left ventricular regions of interest (ROIs) and a stan-
dard ROI in the right lung was measured in three consec-
utive slices, and heart-to-lung ratios were calculated con-
secutively in each volunteer and patient. Heart-to-lung
ratios in the volunteer group did not differ from those in
patients with Parkinson’s disease or MSA (3.2±0.5 vs.
3.2±0.8 and 2.96±0.7, respectively, mean±SD; P=not
significant for all) [56]. Based on the results of our study,
we concluded that human cardiac nAChRs can be visual-
ized and measured by [18F]-2-fluoro-A85380 PET scans
in both cardiac-healthy subjects and patients with
Parkinson’s disease or MSA. Furthermore, these first re-
sults suggest no significant impact of either Parkinson’s
disease or MSA on cardiac nAChRs.
In a second step, we evaluated the feasibility of the
[18F]-2-fluoro-A85380 PET tracer for imaging non-
neuronal vascular α4β2-nAChRs in the same study
population of five healthy controls and six patients with
Parkinson’s disease or MSA [57••]. Again, the aim was
to determine whether this tracer could noninvasively
image vascular α4β2-nAChRs in vivo in humans via
PET and to investigate whether neurodegenerative disor-
ders such as Parkinson’s disease and MSA might have
an impact on the vascular distribution of these nAChRs.
Because of the pathophysiologic importance of nAChRs
in atherosclerosis, which was mentioned earlier, proving
the ability to noninvasively detect nAChRs in humans is
of crucial relevance for the diagnostic and subsequent
therapeutic approach in patients with atherosclerosis. We
therefore quantified [18F]-2-fluoro-A85380 uptake in the
ascending and descending aorta, the aortic arch, and the
carotids in our aforementioned study population as the
maximum target-to-background ratio (Fig. 1). The
maximal standardized uptake value (SUV), single hottest
segment, and percentage of active segments of [18F]-2-
fluoro-A85380 uptake in the arteries also were assessed.
We could clearly visualize the [18F]-2-fluoro-A85380
uptake, and the maximum target-to-background ratio up-
take values corrected for the background activity of the
tracer showed specific tracer uptake in the arterial walls.
Significantly greater uptake values were found in the
descending aorta. Comparison between volunteers and
patients revealed significant differences, with lower
[18F]-2-fluoro-A85380 uptake in the patient group when
single arterial territories were compared but not when
all arterial territories were pooled together [57••]. Our
results clearly suggest that [18F]-2-fluoro-A85380 can
provide specific information on the nAChR distribution
in human arteries. Furthermore, the vascular nAChR
density appears lower in patients with Parkinson’s dis-
ease or MSA, indicating an impact of both neurodegen-
erative disorders on human arteries [57]. Currently, our
group is carrying out studies in larger populations as
well as in the experimental setting to further validate
the approach of noninvasive in vivo imaging of vascular
nAChRs, which will provide more detailed insights into
the pathogenic role of nAChRs in the human vascula-
ture [58].
Recently, Rötering et al. [54••] evaluated a newly de-
veloped α7-nAChR PET tracer ([18F]NS14490) preclini-
cally in an experimental pig model. α7-nAChRs are an
important molecular target in neuropsychiatry and oncolo-
gy, but, as mentioned earlier, also play a crucial role in
the pathophysiologic disease process in atherosclerosis. So
far, the development of applicable highly specific radio-
tracers has been challenging because of comparatively
low protein expression. One novel ligand that might be
a feasible candidate for in vivo PET imaging of cerebral
but also vascular α7-nAChRs is [18F]NS14490. This tracer
was shown to yield reliable results in organ distribution
studies and therefore was tested in a dynamic PET study
in piglets. In this study by Rötering et al. [54••], PET
measurements were performed in young pigs to investigate
the metabolic stability and cerebral binding of
[18F]NS14490 without and with administration of the α7-
nAChR partial agonist NS6740 in baseline and blocking
conditions. Dynamic time–activity curves were calculated
for the frontal cortex, temporal lobe, parietal lobe, occip-
ital lobe, hippocampus, striatum, cerebellum, thalamus,
middle cortex, ventral cortex, midbrain, pons, colliculi, left
carotid artery, and circle of Willis. In addition, to investi-
gate the selectivity of α7-nAChR blockade in the cerebral
vessels, SUV in the left carotid artery, and circle of Willis
was calculated retrospectively (Fig. 2). Assuming complete
blockade of the receptor by the partial agonist, the dis-
placement indicated a specific binding potential of
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[18F]NS14490 in the brain of living pigs, as well as evi-
dence of specific binding in major brain arteries, such as
the carotid arteries. The latter is tremendous because it
appears to enable the PET radiotracer [18F]NS14490 to
image α7-nAChRs in vulnerable plaques of diseased ves-
sels [54••]. Within the next few months, a prospective
study using the α7-nAChR PET tracer and the recently
introduced hybrid PET/MRI technique will begin in pa-
tients with carotid artery disease requiring carotid surgery,
further evaluating the potential of this PET tracer to image
vascular α7-nAChR in atherosclerosis noninvasively.
Current PET Tracers for α4β2 nAChRs
The concept of imaging the α4β2 receptor, as described
earlier, originally was designated for brain receptors. Con-
sequently, several radioligands have been developed,
which are discussed in the following text. Not all the
tracers listed show high affinity, and even in those that
do, it remains to be seen whether they are suitable for
imaging vascular nAChRs, as brain studies generally re-
quire a different approach. For example, the lipophilicity
of a radiopharmaceutical should be high enough to allow
it to penetrate the blood–brain barrier (BBB) for imaging
of brain receptors. However, this is not a requirement in
peripheral imaging; in fact, the lipophilic character of a
drug may even lead to slower blood clearance, preventing
timely image acquisition protocols. On the other hand, a
certain degree of metabolite formation is acceptable in
Fig. 2 Parametric maps of the distribution volume (VT) of [
18F]NS14490
in the brain of piglets. Animal studies were performed without blocked
conditions (controls, upper row) and with pretreatment with the
competitor NS6740 (blocked conditions, lower row). Parametric maps
are projected onto a magnetic resonance atlas for the pig brain. Values
represent the mean of control animals and animals with blocking. Based
on the assumption of a complete blockade, the displacement of the α7-
nAChR PET tracer by the competitor indicates a specific binding poten-
tial in the brain of living pigs, as well as evidence for specific binding in
major brain arteries, such as the carotid arteries. The latter appears to
enable the PET radiotracer [18F]NS14490 to specifically image α7-
nAChRs in vulnerable plaques of diseased arterial vessels. Data are given
in milliliters per gram [54••]. (With permission from: Rötering S,
Deuther-Conrad W, Cumming P, et al.: Imaging of α7 nicotinic acetyl-
choline receptors in brain and cerebral vasculature of juvenile pigs with
[18F] NS14490. EJNMMI Research 2014, 4:43) [89]
Fig. 1 α4β2-nAChR PET/CT scan showing [18F]-2-fluoro-A85380 up-
take in the right and left common carotid arteries (upper ROIs green) and
in the right and left jugular veins (lower ROIs). On a visual basis, the
fused PET/CT image shows higher uptake of the tracer in the two com-
mon carotids compared with the two veins, indicating a specific tracer
uptake in the arteries. Furthermore, the right common carotid artery
shows a higher uptake (SUVmax 1.7 vs. SUVmax 1.2 in the left common
carotid artery) compared with the left common carotid artery, whereas the
uptake in the two jugular veins is almost identical (right SUVmean 1.0 vs.
left SUVmean 1.1), further indicating a specific arterial uptake of the PET
tracer as well as a higher density of the α4β2-nAChRs in the right than in
the left common carotid artery
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brain receptor imaging, provided the radiometabolites
themselves do not cross the BBB. In the periphery, of
course, metabolization of the radiopharmaceutical leads to
poor image quality and interpretation.
[11C]-Nicotine
[11C]-Nicotine was one of the first radioligands used to image
cerebral nicotine receptors [59–62]. The radiosynthesis is
well-developed, with the latest publication reporting a 90 %
decay-corrected yield, 99 % radiochemical purity, and 7- to
11-GBq/μmol-specific activity. Sadly, however, this ligand
shows low specific binding in combination with high nonspe-
cific binding and is metabolized rapidly, rendering the tracer
unsuitable for quantitative applications in human studies. This
is a known disadvantage in brain studies but has a major
impact on imaging applications in the vasculature, in which
metabolites are an even greater complication.
[18F]Nifene
[18F]Nifene [(S)-3-((2,5-dihydro-1H-pyrrol-2-yl)methoxy)-
2-[18F]-fluoropyridine] was synthesized and evaluated for the
first time in an animal model in 2006 by Pichika et al. [63].
Since then, the same group reported an optimized
radiosynthesis (with 6–12 % in-hand yield, 10–20 % decay-
corrected) and more preclinical data, particularly in rats and
rhesus monkeys [64, 65]. So far, their research has shown
[18F]nifene to have rapid brain kinetics and reasonable binding
potential (1.7), whereas its binding in the brain (but not the
cerebellum) could be displaced by nicotine, indicating specific
binding to a nicotinergic receptor, presumably α4β2. Although
some prior optimization must be done to fully characterize
radiometabolites and their in vivo behavior, this tracer appears
to be an available candidate for human studies in the near
future.
[18F]FA
2-[18F]FA and 6-[18F]FA (respectively, (S)-3-(azetidin-2-
methyloxy)-2-[18F]fluoropyridine and (S)-3-(azetidin-
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2methyloxy)-6-[18F]fluoropyridine), also known as 2-[18F]-A-
85380 and 6-[18F]-A-85380, can be synthesized with a high
non-decay-corrected yield of about 50 % [66]. Both are very
polar compounds with a resulting moderate BBB permeation
and slow brain uptake. In combination with the slow washout
rates, requiring scanning up to 6-h post injection, these tracers are
not optimal for brain research. They still are being used, however,
owing greatly to their relatively good specific nAChR binding,
and several publications have appeared both preclinically and
clinically, even in the past few years. In comparing 2-FA with
6-FA, there is a general preference for 2-FA because of its lower
toxicity (15 vs. 1.8 μmol/kg).
Also available is a single-photon emission CT (SPECT)
version of the A-85380 tracer: [123I]-5-IA-85380 ([123I]-5-
IA; [123I]-5-iodo-3-[2(S)-azetidinylmethoxy]pyridine). This
compound has properties necessary for in vivo imaging of
nAChRs with SPECT, including high affinity (dissociation
constant [Kd]=11 pmol/L), rapid entry into the brain, low
nonspecific binding, and minimal toxicity. However, it has
the disadvantage of using an isotope suitable only for SPECT,
with its intrinsic lower resolution and lack of good quantifica-
tion possibilities, but like the 18F-labeled versions, also shows
a slow washout rate [67].
The slow clearance of [18F]FA from the blood (half-life, 6 h)
poses several challenges for vasculature imaging, as late scan
times often are impractical (for patients) and less accurate (be-
cause of potential metabolite build-up). Similar ligands, such as
[18F]nifzetidine and [11C]MA, showed similarly slow kinetics,
rendering this class of ligands feasible but suboptimal for human
use [63, 64, 68].
[18F]ZW-104
[18F]ZW-104 [(S)-3-(azetidin-2-ylmethoxy)-5-(6-[18F]fluorohex-
1-ynyl)pyridine] is a selective ligand for the β2-containing
nAChRs and has a better binding affinity profile than 2-FA
[69]. Radiosynthesis is performed in two steps, followed by
HPLC purification, and shows rather poor yields (3–5 %) and
moderate specific radioactivity. Brain uptake in baboons is high
and specific (demonstrated by the blocking effect of nicotine) and
is better overall than that of [18F]FA; however, it still is charac-
terized by slow kinetics, especially during the washout.
[18F]AZAN-α
[18F]AZAN was developed as an improvement over the
2-[18F]FA and 6-[18F]FA ligands, aiming to increase brain uptake
and washout kinetics while maintaining a high binding affinity
[70, 71]. The precursor currently is available commercially, and
although the synthesis yield is similar to that of [18F]FA (around
50 %), the one-step synthesis is less complex than the two-step
synthesis of [18F]FA compounds (although HPLC purification
still is required), making the radiosynthesis more robust.
After initial trials in baboons confirming specificity and
rapid kinetics (90-min scan time is sufficient), human studies
were conducted [72, 73]. Wong et al. [72] showed that
[18F]AZAN has a favorable dosimetry (0.014 mSv/MBq)
and rapidly enters the human brain, with maximal regional
brain uptake before 20 min post injection. The binding poten-
tial was around 2.5 (slightly better than that of nifene and FA),
and specificity was confirmed by full blockage of uptake by
the smoking cessation drug varenicline, a selective α4β2-
nAChR partial agonist. In terms of stability, three
radiometabolites were found, one of which entered the brain.
It remains to be investigated to what extent these would inter-
fere in the peripheral signal.
[18F]Flubatine
(− ) - [ 1 8F ]F luba t ine [ (− ) - [ 1 8 F ]no rch lo ro - f l uo ro -
homoepibatidine] can be produced with a good yield (60 %)
and high specific activities of >750 GBq/μmol [49, 50••]. The
ligand binds with high affinity and selectivity to the α4β2
receptor subtype. The tracer is very stable in vivo (nearly
90 % at 90 min post injections) and shows only moderate plas-
ma protein binding (15 %). Although never tried in vascular
imaging, this compound seems feasible for this indication.
Another functional enantiomer, (+)-flubatine, similar in
binding characteristics to (−)-flubatine, has a somewhat higher
toxicity (1.5 vs. 6.2 μg/kg for the (−) enantiomer). This tox-
icity is a known problem in epibatine analogues and in the
case of [18F]FPH, with an LD50 of 40 nmol/kg, even forced
discontinuation of research [74, 75].
Current Tracers for α7-nAChRs
Compared with α4β2-nAChRs, the α7 receptor is much
more difficult to visualize in the human brain, mainly
because of its lower expression of about 50 fmol/mg pro-
tein [40]. Similar values were demonstrated in vascular
endothelial cells, with expression levels varying between
53 fmol/mg protein (untreated cells) and 385 fmol/mg
protein (cells exposed to 50-μM nicotine). The steric and
electronic requirements of the orthosteric agonist-binding
site of the α7 receptor are fulfilled by structurally diverse
classes of compounds. Currently, the most promising
agents for molecular imaging in vivo are the substituted
diazabicyclononane derivatives. One of these compounds,
[11C]CHIBA-1001, has been investigated thoroughly in
preclinical and preliminary clinical studies. Similar 18F-la-
beled compounds also have been quite successful, and the
full inventory of currently developed functional
radioligands is described in the following text.
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[11C]A-752274
[11C]A-752274 and [11C]A-833834 both were developed
by the group of Horti et al. [76]. The radioligands were
prepared with a radiochemical yield of 12 to 32 %, high
specific radioactivity (300–400 GBq/μmol), and radio-
chemical purity >95 %. Biodistribution studies in mice
with [11C]A-833834 showed low specific α7-nAChR
binding in the brain, and although [11C]A-752274 spe-
cifically (∼50 %) labeled α7-nAChR in mouse thala-
mus, it exhibited low uptake in baboon brain, thereby
raising questions about its efficacy.
[11C]A-582941 and [11C]A-844606
[11C]A-582941 and [11C]A-844606 were developed in 2009
by the group of Toyohara et al. [77]. The ligands showed
specific uptake in brain regions with highα7 expression; how-
ever, they also were unstable, showing rapid formation of two
metabolites, rendering these tracers unsuitable for peripheral
imaging.
[11C]rac-(1)
[11C]rac-(1) was developed by Gao et al. [78]. The
radiosynthesis was accomplished via N-methylation of
the nor-methyl precursor followed by semipreparative
HPLC purification and 18C solid-phase extraction and
formulation, resulting in an average yield of 30 %, ra-
diochemical purity >98 %, and specific activity of 444±
74 GBq/μmol. Affinity toward the α7-nAChR is about
0.5 nM, which allows in vivo use. In the mouse brain,
[11C]rac-(1) specifically accumulated in the frontal cor-
tex and hippocampus, regions with an elevated density
of α7-nAChRs, whereas uptake in the cerebellum, a
region with low α7-nAChR densities, was nonspecific.
Further research in monkeys, including in vivo displace-
ment studies, are required before human research is per-
formed, but so far the compound seems promising.
[11C]MeQAA
Compared with some of the previously described 11C-labeled
compounds, (R)-2-methylamino-benzoic acid 1-aza-
bicyclo[2.2.2]oct-3-yl ester ([11C]MeQAA) is more stable
and does not produce any metabolites that enter the brain
[79]. This tracer shows an intermediate affinity for the α7-
nAChR (41 nM) in vitro and a (rhesus monkey) brain distri-
bution pattern in vivo that matches the α7 expression distri-
bution, but so far no displacement studies have been
performed.
[76Br]SSR180771 and [11C]CHIBA1001
[ 1 1C ]CH IBA1001 a nd i t s b r om i d e a n a l o gu e ,
[76Br]SSR180771, were developed in 2008 by the group of
Hashimoto et al. [80–82], with further trials conducted
in later years. [76Br]SSR180771 was prepared with an
intermediate yield of 17 % and with high radiochemical
purity and specific activity (respectively, 100 % and
8 GBq/μmol). For [11C]CHIBA1001, the yield was
around 10 %. Although the affinity of these compounds
for α7-nAChR is not optimal (120–180 nM), the uptake
of both compounds in rhesus monkeys was fast and
matched α7 distribution patterns. Furthermore, the brain
uptake could be reduced significantly by using an α7-
receptor specific agonist (SSR180771), but not by an
α4β2-receptor specific ligand (A85380), indicating spe-
cific uptake. Because of the cost of 76Br and the higher
brain uptake of the 11C analogue, preference is given to
[11C]CHIBA for human research. So far, a limited hu-
man study with [11C]CHIBA showed high in vivo plas-
ma stability (>80 % at 60 min post injection) and the
highest brain distribution volume in the thalamus, al-
though regional differences in brain activity were small
[83]. The rather poor affinity of this ligand contraindi-
cates further human research.
[18F]NS10743
[18F]NS10743 was first reported in 2009 by Deuther-Conrad
et al. [84, 85], who produced the tracer from a nitro precursor.
The specific activity exceeded 150 GBq/μmol at a radiochem-
ical purity >99 %. This tracer showed a relatively high affinity
of about 10 nM toward α7 and about 84 nM toward α3β4
in vitro and partially reduced the cortical and hippocampal
binding of tritiated α-bungarotoxin ex vivo. In vivo,
[18F]NS10743 showed rapid uptake in mouse brain, which
could be reduced by SSR180711, a known specific α7 ligand,
thereby proving in vivo specificity.
[18F]ASEM
As a response to poor-affinity ligands such as [11C]CHIBA,
[18F]ASEM (3-(1,4-diazabicyclo[3.2.2]nonane-4-yl)-
6-[18F]fluorodibenzo[b,d]thiophene-5,5-dioxide) was de-
signed [86]. In total, the group of Gao et al. [86, 87] developed
five ligands, each differing by position of the fluorine atom.
Based on in vitro assays and in vivo PET and biodistribution
studies, they concluded that [18F]ASEM (with the 18F in ortho
position from the sulfoxide structure and away from the
diazabicyclononane) showed the most promising characteris-
tics for imaging. [18F]ASEM is produced with a typical yield
of about 16 % (non-decay-corrected) and shows a specific
activity of 300–1200 GBq/μmol and >99 % radiochemical
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purity. Care must be taken during the purification process:
HPLC is required to remove the nitro precursors completely,
as they also have a high affinity toward the α7 receptor. The
radioligand itself is characterized by a subnanomolar affinity
toward α7-nAChR (0.4 nM) and a very high selectivity com-
pared with other nicotinergic receptors [86, 87]. In vivo, the
brain distribution pattern in mice matched that of known α7-
receptor expression and could be decreased significantly by
SSR180771. So far, no human research has been performed
with this ligand, although it appears promising for vascular
research.
[18F]NS14490 and [11C]NS14492
[18F]NS14490 and [11C]NS14492, developed by the group of
Brust et al. [54••, 55, 88], can be synthesized with a 70% yield
and show a good affinity toward α7-nAChR (about 2.5 nM).
Sadly, however, brain uptake is rather low in mice, casting
doubt about their utility for brain research.
Although human data showed mediocre applicability of
this ligand for brain α7-nAChR imaging, imaging of vascular
α7-nAChRs has proven feasible [54••]. The mediocre α7
binding in the brain may be the result of poor BBB permeation
or perhaps of efflux processes by P-glycoprotein, features less
relevant when imaging in the periphery [54••, 55].
Conclusions
During the past several years, interest has been growing
in the use of nAChRs for diagnosing as well as treating
neurologic, oncologic, and vascular disorders. Specific
imaging of neuronal and non-neuronal nAChRs there-
fore is crucial, and PET imaging offers a noninvasive
and easily applicable methodology. Although several
nAChR PET tracers are available today, most are still
in preclinical evaluation or in clinical evaluation for
imaging of cerebral nAChRs in the context of neurode-
generative disorders. However, initial attempts have
been made to apply these tracers to the imaging of
non-neuronal α7- and α4β2-nAChRs in the cardiovas-
cular system. The results of these feasibility studies,
both in humans and in the experimental setting, show
great promise, so further steps toward clinical imple-
mentation of in vivo vascular nAChR PET imaging in
atherosclerosis should be taken. Therefore, research is
under way to further evaluate the tracers available for
clinical imaging of non-neuronal nAChRs, particularly
in patients with known atherosclerosis in the carotid
but also in the coronary arteries, and to develop new
PET tracers for different nAChRs, with the goal of
proving the feasibility of nAChR PET imaging in the
clinical context.
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